TRIA BIOSCIENCE CORPORATION

Basic Information

1616 EASTLAKE AVE E
STE 260
SEATTLE, WA, -

http://triabioscience.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 831016907
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 7


  1. Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients

    Amount: $579,383.00

    DESCRIPTION (provided by applicant): Allergy is a major cause of illness and disability with an estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patien ...

    SBIR Phase I 2013 Department of Health and Human Services
  2. Cross-Protective Monoclonal Antibodies for treatment of pandemic Flu

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Influenza is a highly contagious respiratory disease that causes substantial mortality world-wide. There is great international concern that the Avian Influenza v ...

    SBIR Phase I 2012 Department of Health and Human Services
  3. Advanced Design of a Nicotine Vaccine for Smoking Cessation

    Amount: $352,841.00

    DESCRIPTION (provided by applicant): Tobacco smoke is the primary cause of lung cancer, cardiovascular disease and premature death, with nearly 5 million people dying each year. Treatments that preven ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Protective vaccine for H5N1 Flu using H5 protein and a novel TLR4 agonist.

    Amount: $3,000,000.00

    DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and t ...

    SBIR Phase II 2011 Department of Health and Human Services
  5. A novel DC-targeting non-integrating lentivector vaccine for HIV infection

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): Despite two decades of persistent research on prophylactic and therapeutic immunization against HIV, an effective vaccine-based solution to the HIV pandemic has re ...

    SBIR Phase I 2010 Department of Health and Human Services
  6. Pandemic H5N1 vaccine containing recombinant H5 and a synthetic TLR4 agonist, GLA

    Amount: $756,444.00

    DESCRIPTION (provided by applicant): H5N1 is a highly pathogenic avian influenza virus that can cause severe disease and death in humans. H5N1 is spreading rapidly in bird populations world-wide and t ...

    SBIR Phase I 2009 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government